Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2365 (LINC02365)
- Target
- LINC02365
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
Long intergenic non-protein coding RNA 2365 (LINC02365/LVCAT8) is a long non-coding RNA gene located at chromosome 4q35.1, most studied in the context of hepatocellular carcinoma (HCC). It acts as a tumor suppressor, inhibiting migration, invasion, and metastasis—mainly by regulating the epithelial-mesenchymal transition (EMT) and transcriptionally activating the neighboring gene FOXA2. Its suppression in tumor tissues is associated with poor prognosis, higher metastatic risk, and earlier recurrence in HCC. LINC02365 is frequently listed as a candidate biomarker in liver cancer and is part of a growing group of lncRNAs being evaluated as prognostic indicators and therapeutic targets in oncology research.
- Other names
- LINC02365LVCAT8liver cancer-associated transcript 8
02
Mechanism of action
As a lncRNA, it modulates gene expression (e.g., transcriptional activation of FOXA2 via recruitment of SMAD3, suppression via interaction with EZH2/H3K27Me3 epigenetic modifier).
03
Biological functions
Regulation of epithelial-mesenchymal transition (EMT)Suppression of cell migration and invasionTranscriptional regulation of neighboring genes (e.g., FOXA2)Cell-cell adhesion and extracellular matrix disassembly
04
Disease associations
Cancer (primarily hepatocellular carcinoma, with evidence for roles in gastric, lung, endometrial, and choriocarcinoma)Metastasis suppression in liver cancer
05
Safety considerations
Not directly addressed; typical challenges involve delivery and off-target effects for RNA-based therapies, but no explicit safety risks or toxicity described for targeting this lncRNA.
06
Biomarkers
Downregulation of LINC02365 is a biomarker of poor prognosis, higher metastatic risk, and recurrence-free survival prediction in hepatocellular carcinoma
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2365 (LINC02365).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2365 (LINC02365).